MSD to Acquire EyeBio for up to $3 Billion
US drugmaker Merck & Co. (MSD) has agreed to acquire privately held ophthalmology-focused biotechnology company Eyebiotech (EyeBio).
Ophthalmology
Sandoz Acquires Ophthalmology Franchise from Coherus
In a move to expand its ophthalmic platform, Sandoz, the former generics and biosimilars arm of Swiss drugmaker Novartis, has completed the acquisition of Coherus BioSciences’ subsidiary Coherus Ophthalmology for $170 million.
